Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...

Regeneron acquired a promising weight management asset that could become lucrative. Shares of Regeneron (NASDAQ: REGN) have declined this year due to issues with one of its former growth drivers, ...

Starting July 1, Zepbound will no longer be preferred ... Novo and Lilly have been locked in a fierce competition to dominate the obesity market, which is expected to reach $130 billion by the ...

Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications. Viking ...

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

Financial Stability: Eli Lilly's balance sheet is more robust, with debt making up only 4% of equity, considerably less than ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for ... it will also be adding two new doses, as competition in the space continues to heat ...

Let's consider two corporations that could help you do better than average in the next decade: Eli Lilly (NYSE: LLY) and DexCom (NASDAQ: DXCM). Eli Lilly has been one of the best-performing ...

Even more damaging has been competition from Eli Lilly, the maker of the drug sold as Mounjaro and Zepbound. Novo Nordisk had a head start, winning approval to market its drug for obesity more ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

Lilly and Novo Nordisk NVO presently dominate the market. Mounjaro and Zepbound face strong competition from Novo Nordisk’s semaglutide medicines, Ozempic for diabetes and Wegovy for obesity.